Xiaolin Miao*1, Yiqi Chen*1, Ke Hao†1, Meiqin Zheng‡, Bingyu Chen†, Kaiqiang Li†, Ying Wang†, Wei Zhang§, Yu Zhang§, Xiaozhou Mou§, Shanshan Jiang¶, Zhen Wang‡§
Oncology Research, Vol.26, No.2, pp. 173-182, 2018, DOI:10.3727/096504017X14841698396865
Abstract Glioblastoma is a lethal disease featuring a high proliferation of tumor cells, excessive angiogenesis, and heavy
drug resistance. The overall survival of glioblastoma patients has been dismal, even with an intensive standard
of care. Recent advances in immune checkpoint blockades are changing the treatment of cancers. However,
the efficacy of immune checkpoint blockades in glioblastoma is still unclear. Here we investigated the roles
of CD103+
cells in regulating the effect of immune checkpoint blockades in glioblastoma mouse models. Our
findings indicated that the murine glioblastoma model was not sensitive to immune checkpoint blockades.
Flt3L, a growth More >
Login
Register
